<p> </p>
<p><em>From left to right: James R. Waisman, M.D., Clinical Professor in the Department of Medical Oncology &amp; Therapeutics Research at City of Hope; Michael Brinkenhoff, M.D., Founder &amp; CEO, RevitaLash Cosmetics; Linda Malkas, Ph.D., Deputy Director of Basic Research, Comprehensive Cancer Center at City of Hope</em></p>

 

From left to right: James R. Waisman, M.D., Clinical Professor in the Department of Medical Oncology & Therapeutics Research at City of Hope; Michael Brinkenhoff, M.D., Founder & CEO, RevitaLash Cosmetics; Linda Malkas, Ph.D., Deputy Director of Basic Research, Comprehensive Cancer Center at City of Hope

On November 14, RevitaLash Cosmetics and City of Hope, a leading cancer research and treatment center, hosted the Fourth Annual Gayle Brinkenhoff Breast Cancer Symposium, which brought global research scientists and clinicians together at the City of Hope campus in Duarte, CA.  Highlighting recent developments, advances and best practices in the field and recognizing the potential impact of new developments for personalized breast cancer treatment, the symposium offered research findings to over 120 attendees. 

  “Year over year, I am awe-struck at the breadth of interesting and relevant subjects that each of our guest speakers share at this symposium,” Dr. Michael Brinkenhoff, founder and CEO of RevitaLash Cosmetics, says. “It’s a promising reminder of all the good work being done in the field of breast cancer research, reaching for a cure beyond conventional treatment and looking to the future in a more integrated and holistic approach.”

 At the heart of the RevitaLash Cosmetics brand are its philanthropic endeavors and commitment to breast cancer research and education. This mission is dear to Dr. Brinkenhoff who attributes the creation of RevitaLash Cosmetics to his wife and co-founder, Gayle Brinkenhoff, who was diagnosed with metastatic breast cancer at the age of 32.  

 https://www.revitalash.com/

For reprint and licensing requests for this article, Click here.